We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
IBT.LSE

Price
594.64
Stock movement down
-0.76 (-0.13%)
Company name
International Biotechnology Trust plc
Exchange
(LSE
,
Currency
GBX
)
Sector
Healthcare >
Biotechnology
Markedsværdi
21.57B
Ent værdi
21.59B
Pris/omsætning
556.75
Pris/bog
76.43
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
57.43%
Efterfølgende P/E
638.19
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-8.23%
3 års afkast
-2.27%
5 års afkast
-4.94%
10 års afkast
1.05%
Senest opdateret: 2025-06-22

UDBYTTE

IBT.LSE betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E638.19
Pris til OCF478.84
Pris til FCF759.40
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning556.75
Pris til egenkapital76.43
EV i forhold til salg557.15

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier36.28M
EPS (TTM)0.92
FCF pr. aktie (TTM)0.77

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)38.75M
Bruttofortjeneste (TTM)36.55M
Driftsindkomst (TTM)34.34M
Nettoindkomst (TTM)33.80M
EPS (TTM)0.92
EPS (1 år frem)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)94.32%
Driftsmargin (TTM)88.63%
Fortjenstmargin (TTM)87.24%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter10.43M
Nettotilgodehavender99.00K
Omsætningsaktiver i alt10.65M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver308.15M
Kreditor1.87M
Kortfristet/nuværende langsigtet gæld22.83M
Summen af kortfristede forpligtelser0.00
Sum gæld25.89M
Aktionærernes egenkapital282.26M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)45.05M
Investeringsudgifter (TTM)16.64M
Fri pengestrøm (TTM)28.41M
Udbetalt udbytte (TTM)16.31M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast11.98%
Afkast af aktiver10.97%
Afkast af investeret kapital11.08%
Kontant afkast af investeret kapital9.31%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning610.00
Daglig høj610.00
Daglig lav594.00
Daglig volumen32K
Højeste gennem alle tider858.00
1 års analytiker estimat-
Beta0.21
EPS (TTM)0.92
Udbytte pr. aktie-
Ex-div dato19 Dec 2024
Næste dato for resultatpræsentation-

Nedsidepotensial

Loading...
Nedsidepotensial-data
IBT.LSES&P500
Nuværende prisfald fra top notering-30.69%-3.04%
Højeste prisfald-92.23%-56.47%
Højeste efterår dato8 Dec 19989 Mar 2009
Gennemsnitlig fald fra toppen-41.91%-11.04%
Gennemsnitlig tid til nyt højdepunkt51 days12 days
Maks. tid til nyt højdepunkt4295 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
IBT.LSE (International Biotechnology Trust plc) company logo
Markedsværdi
21.57B
Markedsværdi kategori
Large-cap
Beskrivelse
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
Personale
0
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
UK
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Ingen varer fundet